Trastuzumab deruxtecan binds HER2, is internalized, and releases deruxtecan that inhibits topoisomerase I to cause DNA damage and apoptosis (plus ADCC/bystander effects); killing is driven by HER2 targeting, not by expression of topoisomerase I itself.